Concentration math
Divide labeled material in milligrams by total liquid volume in milliliters to obtain mg/mL.
Research concentration tool
Tesamorelin Dosage Calculator for Laboratory Research
Calculate laboratory stock concentration and measured draw volume for tesamorelin research material.
Measured draw volume
The desired dose is converted into milliliters and corresponding U-100 syringe markings.
Document every variable
Record lot, labeled amount, solvent, final volume, storage, date, controls, and analytical method.
Tesamorelin research
Tesamorelin: what the evidence can and cannot show
Original laboratory-focused answers based on the cited public literature. No competitor FAQ prose is reproduced.
What does the Tesamorelin research calculator report?
It reports theoretical stock concentration and measured draw volume from labeled mass, liquid volume, and a researcher-entered target amount. It does not recommend a human or veterinary dose.
What is Tesamorelin studied for?
Tesamorelin is a GHRH analog used in receptor, pituitary-axis, and downstream signaling research. Literature also exists for a specific regulated prescription formulation and indication.
Which experimental-design variables matter?
Receptor-level activity, GH or IGF-1 markers, formulation, sampling schedule, and intact-axis requirements should be distinguished. A receptor assay cannot reproduce an integrated endocrine system.
How should a researcher interpret the concentration result?
Treat the result as theoretical preparation math. Confirm the exact product label, lot documentation, final volume, material identity, purity, solvent compatibility, storage history, and method suitability before using it in an assay.
What are the evidence and use limitations?
Research-grade tesamorelin is not the approved prescription product and must not be evaluated or used through copied clinical administration instructions.
Scientific references
- Falutz J, Allas S, Kotler D, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005;19(12):1279–1287. View source
- Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: a randomized, placebo-controlled trial. PLoS ONE. 2017;12(6):e0179538. https://pubmed.ncbi.nlm.nih.gov/28617838/ https://doi.org/10.1371/journal.pone.0179538 View source
- U.S. Food and Drug Administration. EGRIFTA SV Prescribing Information. View source
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359–2370. https://pubmed.ncbi.nlm.nih.gov/18057338/ https://www.nejm.org/doi/full/10.1056/NEJMoa072375 View source
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind, placebo-controlled Phase III trials with safety extension data. Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291–4304. https://pubmed.ncbi.nlm.nih.gov/20554713/ https://academic.oup.com/jcem/article/95/9/4291/2835394 View source
- U.S. Food and Drug Administration. EGRIFTA WR Prescribing Information. Revised March 2025. View source
- González-Sales M, et al. Population pharmacokinetic and pharmacodynamic analysis of tesamorelin. 2015. View source
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380–389. https://pubmed.ncbi.nlm.nih.gov/25038357/ https://jamanetwork.com/journals/jama/fullarticle/1889139 View source
- Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719–1728. View source
For research use only
Research-grade tesamorelin is not the approved prescription product and must not be evaluated or used through copied clinical administration instructions. Zeptix Labs catalog materials are not intended for human or veterinary use.
